Zosano Pharma Corporation (ZSAN) Earns News Sentiment Rating of 0.12
Press coverage about Zosano Pharma Corporation (NASDAQ:ZSAN) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zosano Pharma Corporation earned a news impact score of 0.12 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.5790751586677 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Zosano Pharma Corporation (ZSAN) versus Opexa Therapeutics (ACER) Financial Contrast (americanbankingnews.com)
- Kenneth Greathouse Acquires 50,000 Shares of Zosano Pharma Corporation (ZSAN) Stock (americanbankingnews.com)
- Hot Mover to Watch: Zosano Pharma Corporation (NASDAQ: ZSAN) – The Investor Guide (wallstreetnews24.com)
- Zosano Pharma to Present at 29th Annual Piper Jaffray Healthcare Conference (finance.yahoo.com)
- Comparing KemPharm (KMPH) & Zosano Pharma Corporation (ZSAN) (americanbankingnews.com)
Separately, ValuEngine raised shares of Zosano Pharma Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.
Zosano Pharma Corporation (NASDAQ:ZSAN) traded up $0.03 during trading on Monday, reaching $0.68. 667,200 shares of the company traded hands, compared to its average volume of 1,559,585. Zosano Pharma Corporation has a twelve month low of $0.54 and a twelve month high of $3.54.
Zosano Pharma Corporation (NASDAQ:ZSAN) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). analysts forecast that Zosano Pharma Corporation will post -0.79 earnings per share for the current fiscal year.
In related news, Director Kenneth Greathouse purchased 50,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were purchased at an average price of $0.62 per share, with a total value of $31,000.00. Following the completion of the purchase, the director now owns 35,000 shares in the company, valued at approximately $21,700. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 2.95% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Zosano Pharma Corporation (ZSAN) Earns News Sentiment Rating of 0.12” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/20/zosano-pharma-corporation-zsan-earns-news-sentiment-rating-of-0-12.html.
Zosano Pharma Corporation Company Profile
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Stock Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related stocks with our FREE daily email newsletter.